Send to

Choose Destination
Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20.

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Author information

Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France.


Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center